As research support for the C3G Natural History Study team, I work with clinical data to observe the patterns of this ultra-rare kidney disease across our patients' lives. During my time at MORL, I had the privilege of witnessing the FDA approval of the first treatments for C3 Glomerulopathy. I am excited to see how my continued work contributes to future milestones in the advancement of C3G research and care!